Please login to the form below
neurology
This page shows the latest neurology news and features for those working in and with pharma, biotech and healthcare.
Biogen pays Denali $1bn upfront for Parkinson’s disease programme
diseases. We look forward to leveraging our neurology capabilities and infrastructure with Denali’s scientific expertise to accelerate advancement of this programme,” he added.
Latest news
-
Lundbeck drops Parkinson’s drug acquired in €905m deal
Lundbeck is already a big player in neurology and psychological diseases, but has seen its pipeline hit of late with a series of disappointing results, including the failure of Alzheimer’s ... However, it says it will press on with trials of Lu AG06466
-
FDA approves Sanofi’s key cancer drug Sarclisa for myeloma
According to the company’s strategy statement, additional core drivers include treatments for oncology, haematology, rare diseases and neurology.
-
Lilly will aim for one $1bn-$5bn deal per quarter in 2020
oncology, pain, immunology and neurology.
-
Biogen’s R&D chief Ehlers heads for the exit
which has reduced its exposure to high-risk neurology projects.
-
Bluebird Bio reveals further encouraging data for CALD gene therapy
The updated results from the biotech’s phase 2/3 Starbeam study were revealed at the European Paediatric Neurology Society (EPNS) congress in Athens, Greece.
More from news
Approximately 5 fully matching, plus 147 partially matching documents found.
Latest Intelligence
-
The search for treatments for Parkinson’s disease
and a decade as senior director of neurodegenerative diseases research at Merck Serono where he served as its leader for in vitro pharmacology in neurology, including in multiple sclerosis, Parkinson’s
-
20 for 2020 – Five pharma leaders to watch in 2020
returns. That includes an exit from areas like neurology – which predates Bourla’s appointment as CEO but was set up while he was COO – and a series of bolt-on deals
-
25 Women Leaders in UK Healthcare
Lee is now reviewing LifeArc’s portfolio of projects, but sees scope for in-house research on pain, plus networked ‘open innovation’ style collaborative research on underserved areas such as neurology,
-
Brain power: fresh approaches to Alzheimer’s drug discovery
US biotech company Alector, which is pioneering work in immuno-neurology and novel therapeutic approaches to treating neurodegeneration, raised $176m in an initial public offering in early February.
-
Tackling a formidable foe
Ali-Frederic Ben-Amor, Vice President, Global Medical Affairs for Neurology &Immunology, Merck. ... Ali-Frederic Ben-Amor, Vice President, Global Medical Affairs for Neurology &Immunology, Merck, epitomises the field’s passion and refusal to take a
More from intelligence
Approximately 0 fully matching, plus 18 partially matching documents found.
Latest appointments
-
Evoke KYNE appoints global head of digital
O’Donnell joined Evoke in 2017 with experience in engaging healthcare stakeholders across therapy areas and a particular expertise in psychiatry, neurology and diabetes.
-
Porter Novelli adds Amber Tovey to London health team
In her new role at Porter Novelli, Tovey will work across a global pharmaceutical client portfolio that includes neurology, rare diseases and HIV.
-
New faces at W2O, 90TEN and Porterhouse
During her career, Baccari has lead high-profile global initiatives across various therapy areas including neurology, oncology and cardiology.
-
Axovant poaches Allergan’s and Teva’s chief medical and science officers
Corcoran’s career history has seen him supervise drug development across multiple therapeutic areas including neurology and psychiatry.
-
Topas Therapeutics appoints chief development officer and chief medical officer
vice president, multiple sclerosis/neurology and immunology.
More from appointments
Approximately 0 fully matching, plus 33 partially matching documents found.
Latest from PMHub
-
Bedrock Group strengthens its senior team
This experience has provided a strong scientific background across different therapeutic areas, including oncology, nutrition and metabolism, diabetes, obesity, haematology, vaccines, neurology, and rare diseases.
-
Lucid Group adds more magic to the mix with four new hires
Katherine has a background in oncology, neurology, metabolic disorders and genetic diseases.
-
OPEN Health Graduate Programme: from OPEN VIE to OPEN Health Medical Communications
I now have a broad range of experience and connections across the group and have worked across a range of projects and therapy areas including neurology, oncology, ophthalmology and dermatology.
-
The role of brain health in treating MS
Blue Latitude Health speaks to Professor Gavin Giovannoni, key opinion leader and Chair of Neurology, Barts and The London School of Medicine and Dentistry, about his theories on brain health, the ... Rather than treating and reducing relapses, top
-
Diagnosing MS: are we getting it right?
This is even more important when some key opinion leaders within neurology advocate the need to treat early with efficacious drugs for the best chance to delay progression.
More from PMHub
Approximately 7 fully matching, plus 17 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Gilead agrees $21bn buyout of Immunomedics
- Regeneron launches phase 3 COVID-19 antibody trial in the UK
- BioNTech bolsters COVID-19 vaccine capacity with Novartis deal
- Roche’s Ocrevus boasts positive long-term data in MS
- Gavi says 76 wealthy countries have committed to COVAX vaccine facility
- First patients dosed with COVID-19 vaccine from SpyBiotech and Serum Institute of India
- InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping
- Envision Pharma Group scoops two Silvers at the PM Society Digital Awards 2020
- Alone we can do so little, together we can do so much
- What can't we afford to treat anymore?
- OPEN VIE is awarded a Bronze Award at the PM Society Digital Awards 2020
- BioNTech bolsters COVID-19 vaccine capacity with Novartis deal
PMHub
Nucleus Global
Nucleus Global is the largest specialist medical communications network in the world. Globally, we have over 700 experts delivering world-class...
Latest intelligence
- InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping
- Learn how a client engaged 18 rheumatologist advisors over 6 months to create a patient journey map for SLE....
- Alone we can do so little, together we can do so much
- Collaboration is at the heart of successful patient engagement and effective healthcare provision. But in such a complex, nuanced network, true collaborations are rare. So how can we, as an...
- 7 important considerations for creating an inclusive clinical trial website
- You might have noticed that all of us here at COUCH Health are big advocates for taking action to improve diversity and inclusion in the world of clinical research. ‘Taking...
Quick links
Infographics
